Scalable System-Wide CYP2C19 Pharmacogenomic Testing Reveals 38% Excess Incidence of Adverse Events in Metabolizers Receiving Inappropriate Prescriptions
Authors:
- Natalie TelisNTNatalie Telis
- Douglas StollerDSDouglas Stoller
- C. Anwar A. ChahalCCC. Anwar A. Chahal
- Daniel P. JudgeDJDaniel P. Judge
- Joseph J. GrzymskiJGJoseph J. Grzymski
- Catherine HajekCHCatherine Hajek
- Teresa KruisselbrinkTKTeresa Kruisselbrink
- Nicole L. WashingtonNWNicole L. Washington
- Elizabeth T. CirulliECElizabeth T. Cirulli
- 1 June 2026
- journal article
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (3) , e005363
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart AssociationCirculation, 2024
- Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 UpdateClinical Pharmacology & Therapeutics, 2022
- Comprehensive Allele Genotyping in Critical Pharmacogenes Reduces Residual Clinical Risk in Diverse PopulationsClinical Pharmacology & Therapeutics, 2021
- Acute and 1‐Year Hospitalization Costs for Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention: Results From the TRANSLATE‐ACS RegistryJournal of the American Heart Association, 2019
- Clopidogrel Pharmacogenomics and Risk of Inadequate Platelet Inhibition: US FDA RecommendationsPharmacogenomics, 2009